Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development

Modern Pathology

Volumn 25, Issue 8, 2012, Pages 1140-1148

  Sullivan, Peggy S ^a   Maresh, Erin L ^a   Seligson, David B ^a   Habeeb, Omar ^a   Wadehra, Madhuri ^a   Goodglick, Lee ^a   Dorigo, Oliver ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

endometrial cancer; endometrial hyperplasia; immunohistochemistry; normal endometrium; TTF 1

Indexed keywords

THYROID TRANSCRIPTION FACTOR 1;

ADULT; ARTICLE; CANCER RISK; CARCINOGENESIS; CLINICAL FEATURE; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK REDUCTION; TISSUE MICROARRAY;

ADENOCARCINOMA; AGE FACTORS; DISEASE PROGRESSION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MENARCHE; MENOPAUSE; MIDDLE AGED; NUCLEAR PROTEINS; PRECANCEROUS CONDITIONS; PROGNOSIS; RISK FACTORS; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS;

EID: 84864531675     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.64     Document Type: Article

References (35)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
2. Ronnett BM, Zaino RJ, Ellenson LH, et al. Endometrial carcinoma. In: Kurman RJ, Ellenson LH, Ronnett BM (eds). Blaustein's Pathology of the Female Genital Tract 6th edn. Springer: New York, 2011, pp 395-396.
3. Zaino RJ, Kauderer J, Trimble CL, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006; 106:804-811.
4. Allison KH, Reed SD, Voigt LF, et al. Diagnosing endometrial hyperplasia: why is it so difficult to agree? Am J Surg Pathol 2008;32:691-698.
5. Sherman ME, Ronnett BM, Ioffe OB, et al. Reproducibility of biopsy diagnoses of endometrial hyperplasia: evidence supporting a simplified classification. Int J Gynecol Pathol 2008;27:318-325.
6. Boggaram V. Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin Sci 2009;116:27-35.
7. Ordonez NG. Thyroid transcription factor-1 is a marker of lung and thyroid carcinoma. Adv Anat Pathol 2000; 7:123-127.
8. Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 2000;13:238-242.
9. Robens J, Goldstein L, Gown AM, et al. Thyroid transcription factor-1 expression in breast carcinomas. Am J Surg Pathol 2010;34:1881-1885.
10. Fujiwara S, Nawa A, Nakanishi T, et al. Thyroid transcription factor 1 expression in ovarian carcinomas is an independent prognostic factor. Hum Pathol 2010; 41:560-565.
11. Zhang PJ, Gao HG, Pasha TL, et al. TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. Int J Gynecol Pathol 2008;28:10-18.
12. Alkushi A, Irving J, Hsu F, et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 2003;442:271-277.
13. Kubba LA, McCluggage WG, Liu J, et al. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol 2008;21:485-490.
14. Siami K, McCluggage WG, Ordonez NG, et al. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. Am J Surg Pathol 2007;31:1759-1763.
15. Niu H, Pasha TL, Pawel BR, et al. Thyroid transcription factor-1 expression in normal and gynecologic tissues and its potential significance. Int J Gynecol Pathol 2009;28:301-307.
16. Saito RA, Watabe T, Horiguchi K, et al. Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells. Cancer Res 2009;69:2783-2791.
17. Winslow MM, Dayton TL, Verhaak RGW, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 2011;473:101-108.
18. Habeeb O, Goodglick L, Soslow RA, et al. Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development. Cancer 2010;116: 4718-4726.
19. Silverberg SG, Kurman RJ, Nogales F, et al. Tumors of the uterine corpus. In: Tavassoli FA, Devilee P (eds). World Health Organization Classification of Tumors, Pathology and Genetics, Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, France, 2003.
20. Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol 1996;9:445-452.
21. Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology 2000;36:415-420.
22. Hecht JL, Pinkus JL, Weinstein LJ, et al. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin. Am J Clin Pathol 2001;116:483-488.
23. Han CP, Kok LF, Lee MY, et al. Five commonly used markers (p53, TTF1, CK7, CK20, and CK34betaE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. Arch Gynecol Obstet 2010;281:317-323.
24. Graham AD, Williams ARW, Salter DM. TTF-1 expression in primary ovarian epithelial neoplasia (correspondence). Histopathology 2006;48:764-776.
25. Berghmans T, Paesmans M, Mascaux C, et al. Thyroid transcription factor 1-A new prognostic factor in lung cancer: a meta-analysis. Ann Oncol 2006;17: 1673-1676.
26. Perner S, Wagner PL, Soltermann A, et al. TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol 2009;217:65-72.
27. Anagnostou VK, Syrigos KN, Bepler G, et al. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol 2009;27:271-278.
28. Baron JA, La Vecchia C, Levi F. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol 1990;162:502-514.
29. Ganti AK, Sahmoun AE, Panwalkar AW, et al. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 2006;24:59-63.
30. Minaguchi T, Nakagawa S, Takazawa Y, et al. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Lett 2007;248:112-122.
31. Monte NM, Webster KA, Neuberg D, et al. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. Cancer Res 2010;70:6225-6232.
32. Llobet D, Pallares J, Yeramian A, et al. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol 2009;62:777-785.
33. Dellas A, Jundt G, Sartorius G, et al. Combined PTEN and p27kip1 protein expression patterns are associated with obesity and prognosis in endometrial carcinomas. Clin Cancer Res 2009;15:2456-2462.
34. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92: 924-931.
35. Lacey Jr JV, Mutter GL, Ronnett BM, et al. PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res 2008;68: 6014-6020.